Status:
ACTIVE_NOT_RECRUITING
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Lead Sponsor:
NGM Biopharmaceuticals, Inc
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Pancreatic Cancer
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Eligibility Criteria
Inclusion
- Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.
- Adequate bone marrow, kidney and liver function
- Performance status of 0 or 1.
- Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.
Exclusion
- Prior treatment targeting ILT3.
- Prior treatment targeting LAIR1.
Key Trial Info
Start Date :
March 31 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT05215574
Start Date
March 31 2022
End Date
March 1 2026
Last Update
October 10 2024
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
NGM Clinical Study Site
Gilbert, Arizona, United States, 85234
2
NGM Clinical Study Site
Los Angeles, California, United States, 90025
3
NGM Clinical Study Site
Sarasota, Florida, United States, 34232
4
NGM Clinical Study Site
Tampa, Florida, United States, 33612